KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Equity Average (2016 - 2025)

Boston Scientific's Equity Average history spans 17 years, with the latest figure at -$288.5 million for Q2 2025.

  • For Q2 2025, Equity Average fell 130.68% year-over-year to -$288.5 million; the TTM value through Jun 2025 reached -$288.5 million, down 130.68%, while the annual FY2025 figure was $23.1 billion, 11.97% up from the prior year.
  • Equity Average for Q2 2025 was -$288.5 million at Boston Scientific, down from $10.9 billion in the prior quarter.
  • Across five years, Equity Average topped out at $19.3 billion in Q4 2023 and bottomed at -$288.5 million in Q2 2025.
  • The 5-year median for Equity Average is $9.9 billion (2021), against an average of $9.5 billion.
  • The largest annual shift saw Equity Average soared 17200.0% in 2024 before it tumbled 130.68% in 2025.
  • A 5-year view of Equity Average shows it stood at $7.1 billion in 2021, then surged by 166.9% to $19.0 billion in 2022, then grew by 1.92% to $19.3 billion in 2023, then crashed by 95.13% to $940.5 million in 2024, then tumbled by 130.68% to -$288.5 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Equity Average are -$288.5 million (Q2 2025), $10.9 billion (Q1 2025), and $940.5 million (Q2 2024).